Employees: 11-50
Investment Stage: Series A
Portfolio 5
| Date | Name | Website | Total Raised | Location |
| 03.06.2020 | Prilenia T... | prilenia.com | $105.5M | Israel, Te... |
| 17.11.2015 | Amylyx | amylyx.com | $171.9M | - |
| - | Emulate, I... | emulatebio.com | $175.75M | United Sta... |
| - | Verge Geno... | vergegenomics.com | $68M | United Sta... |
| - | Orphazyme ... | orphazyme.com | $41.84M | Denmark, C... |
Mentions in press and media 8
| Date | Title | Description |
| 19.09.2024 | Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer | NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative dise... |
| 12.03.2024 | Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative disease... |
| 07.01.2022 | Amylyx Pharma’s IPO lands $190M as ALS drug begins FDA review | Amylyx Pharmaceuticals has joined the public markets with a $190 million IPO that will support the company as it shepherds its amyotrophic lateral sclerosis drug through regulatory review, and if all goes well, a commercial launch as a new ... |
| 20.07.2021 | Amylyx Pharmaceuticals Closes $135M Series C Financing Led by Viking Global Investors to Support Late Stage Development of Lead Product Candidate AMX0035 for the Treatment of ALS | Amylyx Pharmaceuticals, Inc. today announced the closing of an oversubscribed $135 million Series C financing, led by Viking Global Investors, to support the clinical development and potential launch plans for lead product candidate AMX0035... |
| 03.06.2020 | Prilenia Therapeutics : Raises $62.5m to Fund Late Stage Trials in HD and ALS | Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announces that is has raised $62.5M in a Series A financing round to launch the Comp... |
| 17.11.2015 | Amylyx gets $1.9M for ALS, Alzheimer’s drug that mediates organelle stress | “The ALS Finding a Cure Foundation is committed to pursuing multiple avenues toward a cure for ALS,” Merit Cudkowicz, the foundation’s chief medical officer as well as chief of neurology at Massachusetts General Hospital, said in a statemen... |
| - | Amylyx gets $1.9M for ALS, Alzheimer’s drug that mediates organelle stress | Cambridge startup Amylyx Pharmaceuticals is developing a new combination drug product that could help treat neurodegenerative diseases like ALS, Alzheimer’s disease and mitochondrial disorders. It just raised $1.3 million in a new equity ro... |
| - | Amylyx Pharma’s IPO lands $190M as ALS drug begins FDA review | Amylyx Pharmaceuticals has joined the public markets with a $190 million IPO that will support the company as it shepherds its amyotrophic lateral sclerosis drug through regulatory review, and if all goes well, a commercial launch as a new ... |